| Record ID | marc_loc_2016/BooksAll.2016.part42.utf8:79681622:1354 |
| Source | Library of Congress |
| Download Link | /show-records/marc_loc_2016/BooksAll.2016.part42.utf8:79681622:1354?format=raw |
LEADER: 01354cam a22003498i 4500
001 2015031036
003 DLC
005 20151017082654.0
008 150807s2016 flu b 001 0 eng
010 $a 2015031036
020 $a9781498743471 (hardcover : alk. paper)
035 $a(DNLM)101665454
040 $aDNLM/DLC$cDLC$erda$dDLC
042 $apcc
050 00 $aRS380
060 10 $aQV 241
082 00 $a338.4/76151$223
100 1 $aNiazi, Sarfaraz,$d1949- ,$eauthor.
245 10 $aBiosimilars and interchangeable biologics :$bstrategic elements /$cSarfaraz K. Niazi.
263 $a1512
264 1 $aBoca Raton :$bTaylor & Francis,$c2016.
300 $ap. ;$ccm.
336 $atext$2rdacontent
337 $aunmediated$2rdamedia
338 $avolume$2rdacarrier
504 $aIncludes bibliographical references and index.
505 0 $aIntroduction to biosimilar and interchangeable products -- Intellectual property issues -- The EMA regulatory guidance -- EMA approved biosimilars -- The FDA regulatory guidance -- The ROW regulatory guidance -- US commercialization -- Global commercialization -- Quality and lifecycle management.
650 12 $aBiosimilar Pharmaceuticals$xstandards.
650 22 $aDrug Approval.
650 22 $aDrug Discovery$xstandards.
650 22 $aDrug Evaluation$xstandards.
650 22 $aDrug Industry$xstandards.